Corrigendum to “Ceftriaxone administration reduces vascular calcification associated with experimental models of chronic kidney disease.” [Biomed. Pharmacother. 197 (2026), 119131] - 23/04/26
Doi : 10.1016/j.biopha.2026.119339
Teresa Obrero-Sojo a, Ma José Jiménez-Moral c, f, Fátima Guerrero c, f, Ma Encarnación Rodríguez-Ortiz c, f, Ana Isabel Torralbo a, f, Karen Valdés-Díaz c, Raquel Ma García-Sáez a, Antonio Rivas-Domínguez a, Daniel Jurado-Montoya a, Fernando Leiva-Cepas d, Ma Victoria Pendón-Ruiz de Mier a, b, f, Cristian Rodelo-Haad a, b, f, Griet Glorieux e, Mariano Rodríguez a, b, f, Sagrario Soriano-Cabrera b, 1, Juan Rafael Muñoz-Castañeda a, b, f, 1, ⁎ 
a Research Group: "Calcium Metabolism. Vascular Calcification", Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofia University Hospital, Córdoba, Spain
b Nephrology Service, Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Spain
c Research Group: "Nephrology. Cellular damage in chronic inflammation", Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba, Reina Sofia University Hospital, Spain
d Department of Morphological Sciences (Histology Section), Faculty of Medicine and Nursing, University of Córdoba, Spain
e Department of Internal Medicine and Pediatrics, Nephrology Division, Ghent University Hospital, Ghent 9000, Belgium
f Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS, RD24/0004/0004), Carlos III Health Institute, Madrid 14 28029, Spain
⁎ Correspondence to: Calcium Metabolism, Vascular Calcification, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba (Spain), Reina Sofia University Hospital, Córdoba, Nephrology Service, Reina Sofia University Hospital, Córdoba, Spain Calcium Metabolism, Vascular Calcification, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Córdoba (Spain), Reina Sofia University Hospital, Córdoba, Nephrology Service, Reina Sofia University Hospital, Córdoba Spain
Le texte complet de cet article est disponible en PDF.
© 2026
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 198
Article 119339- mai 2026 Retour au numéro
Article précédent
- Corrigendum to Anisamide-conjugated hairpin antisense oligonucleotides prodrug co-delivering doxorubicin exhibited enhanced anticancer efficacy [BIOPHA, 173 (2024) 116390]
- Zhe Zhang, Zuyi Chen, Shuangshuang Liu, Zhenyu Xiao, Yuan Luo, Xiaochen Pan, Xuesong Feng, Liang Xu
- Retraction notice to "Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies" [Biomedicine & Pharmacotherapy 160 (2023) 114392]
- Mehrdad Hashemi, Mohammad Arad Zandieh, Yasmin Talebi, Parham Rahmanian, Sareh Sadat Shafiee, Melina Maghsodlou Nejad, Roghayeh Babaei, Farzaneh Hasani Sadi, Romina Rajabi, Zahra Oryan Abkenar, Shamin Rezaei, Jun Ren, Noushin Nabavi, Ramin Khorrami, Mohsen Rashidi, Kiavash Hushmandi, Maliheh Entezari, Afshin Taheriazam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?